i&i Biotech Fund

i&i Biotech Fund operates as a Luxembourg-headquartered venture capital organization dedicated to financing cutting-edge European life sciences ventures. Managing assets exceeding €53 million, the fund strategically allocates capital to promising early-stage enterprises across pharmaceuticals, medical technology, diagnostic solutions, and digital healthcare platforms. Their investment portfolio aims to encompass approximately 20 carefully selected companies demonstrating exceptional innovation potential and addressing significant healthcare challenges.

The fund benefits from leadership by a diverse team of seasoned professionals whose collective expertise spans private equity operations, healthcare industry knowledge, and venture capital investment strategies. These specialists provide comprehensive support beyond mere financial backing, offering strategic guidance, industry connections, and operational insights to help portfolio companies navigate complex regulatory environments and scale effectively. Their hands-on approach enables emerging biotech entrepreneurs to transform promising research into commercially viable healthcare solutions with global impact.

A distinctive competitive advantage for i&i Bio stems from its strategic partnership with i&i Prague, a renowned biotech academic incubator serving as the fund's primary sponsor. This collaboration creates a privileged pipeline to groundbreaking Central European technologies at their earliest developmental stages, often before they become visible to broader investment markets. The relationship facilitates access to cutting-edge academic research, scientific talent, and emerging innovations across the region's research institutions and universities, positioning i&i Bio at the forefront of transformative healthcare discoveries.

The fund's investment philosophy emphasizes identifying disruptive technologies addressing substantial unmet medical needs while maintaining rigorous scientific validation standards. Typically engaging at seed and Series A stages, i&i Bio provides both capital infusion and strategic development support to accelerate commercialization pathways. Their geographic focus prioritizes European innovation hubs with particular emphasis on Central European biotech ecosystems that remain underserved by traditional venture capital despite producing world-class scientific research. This regional specialization, combined with deep scientific expertise and commercial acumen, enables i&i Bio to identify and nurture promising healthcare innovations that might otherwise struggle to secure adequate funding.